Similar articles

• Lasofoxifene for postmenopausal women with osteoporosis.

  Silva-Fernández L, Andreu JL. Silva-Fernández L, et al. N Engl J Med. 2010 Jun 10;362(23):2228; author reply 2228-9. N Engl J Med. 2010. PMID: 20568310 No abstract available.
• Lasofoxifene: new drug. Osteoporosis: no better than raloxifene.

  [No authors listed] [No authors listed] Prescrire Int. 2009 Dec;18(104):247. Prescrire Int. 2009. PMID: 20020572 No abstract available.
• Lasofoxifene in postmenopausal women with osteoporosis.

  Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong RA, Thompson DD, Powles T, Zanchetta J, Kendler D, Neven P, Eastell R; PEARL Study Investigators. Cummings SR, et al. N Engl J Med. 2010 Feb 25;362(8):686-96. doi: 10.1056/NEJMoa0808692. N Engl J Med. 2010. PMID: 20181970 Clinical Trial.
• Lasofoxifene: selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.

  Peterson GM, Naunton M, Tichelaar LK, Gennari L. Peterson GM, et al. Ann Pharmacother. 2011 Apr;45(4):499-509. doi: 10.1345/aph.1P604. Epub 2011 Apr 5. Ann Pharmacother. 2011. PMID: 21467260 Review.
• [Absolute risk for fracture and WHO guideline. Selection of drugs for the prevention of fractures in postmenopausal women].

  Gorai I; World Health Organization. Gorai I, et al. Clin Calcium. 2007 Jul;17(7):1090-6. Clin Calcium. 2007. PMID: 17607077 Review. Japanese.